Search

Jonathan Feld, MD

Oncology and Hematology
Jonathan Feld, MD
Areas of Focus
Jonathan Feld, MD
Locations

Memorial Division of Hematology & Oncology

1750 East Hallandale Beach Boulevard
Hallandale, FL 33009

Phone: 954-265-4325

Fax: 954-276-0765

Get Directions

Memorial Division of Hematology & Oncology

12235 Pines Boulevard
Pembroke Pines, FL 33026

Phone: 954-265-4325

Fax: 954-276-0747

Get Directions

Memorial Division of Hematology & Oncology

1150 North 35 Avenue
Suite 330
Hollywood, FL 33021

Phone: 954-265-4325

Get Directions

Memorial Division of Hematology & Oncology

1150 North 35th Avenue
Suite 170
Hollywood, FL 33021

Phone: 954-265-4325

Get Directions

About Me

I am a hematologist-oncologist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Health Care System. I care for patients with all types of blood cancers, specializing in myeloid malignancies and leukemias, with a particular focus on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and large granular lymphocyte leukemia (LGL).

Cancer care has changed dramatically in recent years, and I’ve been drawn to the pace of discovery and innovation in hematologic oncology. At the same time, there’s still so much work to be done, especially for diseases like MDS, where treatment options remain limited. As a native South Floridian, I’m committed to expanding clinical research and treatment options here, so patients don’t have to travel far to receive the level of care they deserve.

My interest in MDS and leukemia began during the summer after my first year of medical school, when I worked in the lab of a leading expert in MDS. That experience sparked my fascination with the disease from both a scientific and clinical perspective, and it continues to shape my research and practice today.

What I find most meaningful is seeing patients reach the moments that matter—celebrating milestones, spending time with family and feeling well enough to enjoy life again. I love hearing their stories and seeing the photos they share. I try to bring optimism and honesty to every conversation. Many of the conditions I treat are complex or chronic, and I believe in helping patients make decisions that align with their values and goals. 

Prior to joining Moffitt at Memorial, I served as an assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, where I also specialized in MDS and leukemias.  

In addition to caring for patients, I’m actively involved in research and education. I was selected for the ASCO/AACR Methods in Clinical Cancer Research (Vail) Workshop, where I designed a trial for patients with MDS, and I received the Hematology/Oncology Faculty Teaching Award at Mount Sinai. My research mirrors my clinical work—I’ve been an investigator on multiple trials in MDS, AML and ALL (acute lymphoblastic leukemia) and my translational research has explored how the immune system may contribute to bone marrow failure in MDS. These research efforts have been presented at national and international meetings. I look forward to bolstering Memorial's clinical trial portfolio for patients with leukemias to bring these novel therapies to our patients.

Languages

  • English

Areas of Focus

  • Acute myeloid leukemia (AML)
  • Blood cancers
  • Large granular lymphocyte leukemia (LGL)
  • Leukemias
  • Myeloid malignancies
  • Myelodysplastic syndromes (MDS)

Education

Fellowships

  • Icahn School of Medicine - Hematology/Medical Oncology Fellowship, 2021, Oncology and Hematology

Residency

  • Beth Israel Deaconess Medical Center - Internal Medicine Residency, 2018, Internal Medicine

Medical Education

  • Albert Einstein College of Medicine, 2015

Certifications

  • American Board of Internal Medicine-Hematology
  • American Board of Internal Medicine-Internal Medicine
  • American Board of Internal Medicine-Medical Oncology

Awards, Achievements, and More

Publications

Please view Dr. Jonathan A. Feld’s publications on PubMed.

Professional Organizations

  • American Society of Hematology
  • American Society of Clinical Oncology
  • European Hematology Association

Presentations

Media presentations

  • Good Rx Media Session regarding MDS & Anemia (4/2023, 3/2025)
  • HealthTree University Media Session regarding MDS (5/2023)

Abstract presentations

  • Desai SR, Handa S, Chandhok N, Van Hyfte G, Guo QJ, Coltoff A, Twardowksi N, Okoniewski M, Gonzalez-Lugo JD, Hoff F, Anderson J, Madanat Y, Wang T, Ibrahim U, Tremblay D, Moshier E, Silverman LR, Shastri A, Feld J (2025) Role Of Pre-Transplant Molecular Remission On Outcomes Of Allogeneic Stem Cell Transplant In Myelodysplastic Syndromes. Presented at: European Hematology Association annual meeting; Milan, Italy
  • Murthy G, Ball S, Feld J, et al. (2024) Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Handa S, Riazat-Kesh Y, Butterfield RJ, Sivakumar G, Venugopal S, McGovern E, Feld J, et al. (2024). TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Rai R, Feld J, et al. (2023) Establishing a Pathogenic Role for NK Cells As Drivers of Bone Marrow Failure in the Myelodysplastic Syndromes (MDS). Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Handa S, Chandhok N, Desai SR, Berkalieva A, Moshier E, Tremblay D, Silverman LR, Wang T, Ibrahim U, Shastri A, Feld J (2023). Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Nathan D, Hoffman R, Ahire D, Mascarenhas J, Silverman LR, Najfeld V, Feld J (2023). The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Tremblay D, Van Hyfte G, Mascarenhas J, Feld J (2023). Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Tremblay D, Shih A, Feld J, Moshier E, Mascarenhas J (2023). Phase 1/2 Study of Pacritinib in Combination with Azacitidine in Chronic Myelomonocytic Leukemia. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Tremblay D, Csizmar CM, DiNardo CD, Ball S, Rippel N, Hammond DE, Kadia TM, Ravandi F, Chien KS, Hyfte GV, Saliba A, Mangaonkar AA, Lasho TL, Al-Kali A, Kremyanskaya M, Feld J, et al (2023). Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis. Presented at: American Society of Hematology annual meeting; San Diego, CA.
  • Rai R, Bigenwald C, Feld J, et al. (2022) Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients. Presented at: American Society of Hematology annual meeting; New Orleans, LA.
  • Balev M, Zubizarreta N, Bresnahan E, Feld J, et al. (2022) Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European LeukemiaNet (ELN) Risk Classification. Presented at: American Society of Hematology annual meeting; New Orleans, LA.
  • Rai R, Patel F, Feld J, et al. (2021) Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line. Presented at: American Society of Hematology annual meeting; Atlanta, GA.
  • Bhalla S, Bakouny Z, Schmidt AL, Steinharter JA, Tremblay D, Awad MM, Kessler AJ, Haddad R, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, et al (2021). Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study. American Association of Cancer Research. Virtual Meeting: COVID-19 & Cancer.
  • Feld J, Demakos E, Odchimar-Reissig R, et al. (2020) Myelodysplastic Syndromes & COVID-19: Clinical Experience from the US Epicenter of the Pandemic. Presented at: American Society of Hematology annual meeting; Virtual.
  • Feld J, Houldsworth J, Reddy A, et al. (2020) T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG. Presented at: American Society of Hematology annual meeting; Virtual.
  • Doroshow D, Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay D, Awad MM, Kessler AJ, Bouchard G, Evans M, Busser F, Zimmerman BS, Curran CR, Jun T, Haddad R, Qin Q, Nuzzo PV, Feld J, Galsky MD, Choueiri TK (2020). Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). Presented at: European Society of Medical Oncology annual meeting; Virtual.
  • Feld J, Schieppati F, Odchimar-Reissig R, et al. (2019). T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin. Presented at: American Society of Hematology annual meeting; Orlando, FL.
  • Shastri A, Teixeira M, Bhattacharyya S, Ramachandra N, Lopez R, Ravipati, G, Feld J, et al. (2017) Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3. Presented at: American Society of Hematology annual meeting; San Diego, CA.

Awards

  • Mount Sinai Hematology/Oncology Faculty Teaching Award – Benign Hematology/Malignant Hematology, 2025
  • Fellow of the Month, Mount Sinai Health System, New York, NY, 2021
  • SOHO Young Investigator Grant, 2019
  • Nurse/MD Appreciation Day Housestaff Award, Veterans Affairs, West Roxbury, MA, 2016
  • MD with Distinction in Research, 2015
  • Alpha Omega Alpha Medical Honor Society, 2015
  • Albert Einstein College of Medicine-Karolinska Institute Exchange Program, 2015
  • Service and Research Scholar, Albert Einstein College of Medicine, 2011

Hospital Affiliations